A Phase 2 interventional study of Dexmedetomidine and Placebo administration in Anesthesia and Pediatric Surgery, sponsored by University Hospital, Montpellier. Recruiting at 1 site in France. Open to participants aged 1 Year to 7 Years. Per ClinicalTrials.gov, last updated 2026-10-13.
Sponsored by University Hospital, Montpellier · Phase 2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 64 studies testing dexmedetomidine in Pain — 11 open to participants now, 12 under way, 2 of them phase 3. Dexmedetomidine · Pain.
Among the 64 studies testing dexmedetomidine in Pain, this one is the 4th largest by planned enrollment of the 63 interventional ones that give a count, is one of 6 that started in 2025, is one of 8 in phase 2, reaches primary completion later than 10 of the 11 other live ones, and was the 53rd registered.
10,076 studies on the registry are indexed under Pain; 1,648 are open to participants now.
Browse Pain studies →11 of the 64 studies testing dexmedetomidine in Pain are open now, in 7 countries. Recruiting first, the newest first:
Fatima Memorial Hospital · Sites in Pakistan
Ages 18–60
Tanta University · Sites in Egypt
Ages 40–75
Assaf-Harofeh Medical Center · Sites in Israel
Ages 4 wk+
Beni-Suef University · Sites in Egypt
Ages 18+
Göteborg University · Sites in Sweden
Ages 18+
By country, each count listing its studies:
Dexmedetomidine: first FDA approval 1999 (PRECEDEX), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →
Of the 930 Pain studies recruiting now, 384 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 220 take healthy volunteers.
This study: 1 Year to 7 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
64 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 10 · Phase 3 9 · Phase 4 22
First in 2006; this study’s year is marked. 6 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 200 is above the median of 66 across 8,512 interventional studies indexed under Pain.
Median enrollment 70 across the 63 interventional studies. Of the 43 that completed or were terminated, 14 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 64 have an industry lead sponsor. The 10 most frequent:
University Hospital, Montpellier is the lead sponsor of 1,264 studies on the registry; 226 are open to participants now.
15 studies in Pain by University Hospital, Montpellier: 3 open now, 3 under way, none of them phase 3. Of 9 finished, 0 (0%) have results posted.
Among the 15 studies in Pain by University Hospital, Montpellier, this one is one of 2 that started in 2025, is the only one in phase 2, and was the 14th registered.
University Hospital, Montpellier’s Pain studies by the year they started, since 2009.
None of the studies under way reaches primary completion within a year.
Among the 64 studies testing dexmedetomidine in Pain, from their registry updates:
Among University Hospital, Montpellier’s 15 in Pain:
This tab as a report to print or save as PDF → With an account.
The main objective of this study is to study the impact of intravenous dexmedetomidine combined with locoregional anesthesia on postoperative pain in children undergoing surgery.
Secondary objectives was to compare beetwen groups : Post-operative pain; opioid consumption; incidence of emergence delirium, post-operative behavioral disorders, length of stay in the PACU, adverse events , parental satisfaction and quality of life.The goal of this clinical trial is to assess intravenous dexmedetomidine to prevent post-operative pain in children undergoing surgery.
This study is prospective and children will be randomized in one of the following arm:
Participants and their legal representative will have to respond to questionnaires at several time points following the surgery: Day 1, Week 1, Month 3 and Month 6.
Postoperative pain, which can develop into chronic pain in children, can have a significant impact on the quality of life of the child and their parents. Management of acute postoperative pain is crucial to prevent chronic pain, and perioperative opioid sparing aims to reduce opioid side effects. The emergence of postoperative delirium (ED) is also a concern, as it can cause intense agitation and diagnostic difficulties. Dexmedetomidine, in addition to its sedative and analgesic effects, has been shown to prolong the duration and effectiveness of regional anesthesia (LAR), thereby reducing the need for opioids and attenuating the severity of postoperative delirium. Its use in these settings could improve pain management and reduce complications associated with pediatric surgery, thus offering a promising therapeutic option.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Intravenous administration of 1 µg /kg of dexmedetomidine in 10 ml of 0.9% sodium chloride at the time of incision.
Drug: Dexmedetomidine · Other: Face Legs Activity Cry Consolability scale · Other: Post-Hospitalization Behavior Questionnaire · Other: Postoperative pain measure · Other: Post-operative quality of life questionnaire
Intravenous administration of 10 ml sodium chloride 0.9% at the time of incision
Drug: Placebo administration · Other: Face Legs Activity Cry Consolability scale · Other: Post-Hospitalization Behavior Questionnaire · Other: Postoperative pain measure · Other: Post-operative quality of life questionnaire
Intravenous administration of 1 µg /kg of dexmedetomidine in 10 ml of 0.9% sodium chloride at the time of incision.
Intravenous administration of 10 ml sodium chloride 0.9% at the time of incision
The pain will be assessed on admission and every 15 minutes until discharge from the PACU
The Post-Hospitalization Behavior Questionnaire will be completed at day 1 and at day 7
The Postoperative pain measure will be completed by parents at day 1, day 7, 3 months and 6 months
The Post-operative quality of life questionnaire pedQL will be completed at 3 and 6 months
Rescue analgesic
Rescue analgesic (Nalbuphine, Nubain®) administration in the PACU between the 2 arms.
Time frame: From the end of surgery to hospital discharge (up to 7 days)
Postoperative pain
Assessment of postoperative pain using the Face Legs Activity Cry Consolability (FLACC) scale: on admission and every 15 minutes until discharge from the PACU, then before returning home.
Time frame: From the end of surgery to hospital discharge (up to 2 days)
Intraoperative morphine consumption
Time frame: From anesthesia induction to the end of surgery (up to 24 hours)
Emergency analgesics
Dose in milligrams of emergency analgesics in the PACU
Time frame: From the end of surgery to hospital discharge (up to 24 hours)
Adverse events
Incidence of opioid-related side effects (respiratory complications - postoperative nausea and vomiting)
Time frame: From the end of surgery up to 7 postoperative days
Length of hospital stay
Length of hospital stay in hours from admission to discharge
Time frame: From the start of hospitalization to hospital discharge (up to 7 days)
Ped-PADSS score
The Post-Anesthetic Discharge Scoring System aimed to assess the possibility of discharge. The minimum is 0 and the maximum 10. A score of 9 or 10 authorizes hospital discharge.
Time frame: From the end of surgery to hospital discharge (up to 2 days)
Pediatric Anesthesia Emergence Delirium
Incidence of emergence of delirium in the PACU according to the Pediatric Anesthesia Emergence Delirium (PAED) scale. Score from 0 to 20, a score \> 9 indicates an emergence delirium
Time frame: From the end of surgery to hospital discharge (up to 24 hours)
Post-Hospitalization Behavior Questionnaire
Post-Hospitalization Behavior Questionnaire at day 1 and day 7. This questionnaire is composed of 27 items rated from 1 to 5, minimum score : 27, maximum score: 135. A score above 68 is associated with an increase in postoperative behavioral problems.
Time frame: From the end of surgery up to 6 postoperative months
Postoperative Pain Measure For Parents
Postoperative Pain Measure For Parents at 7 days, 3 and 6 months. Score: from 0 to 10 with 10 items. A score above 6 indicates significant pain.
Time frame: From the end of surgery up to 6 postoperative months
Post-operative quality of life questionnaire
Post-operative quality of life questionnaire pedsQL at 3 and 6 months. The 23 questions cover 4 different domains: physical functioning (8 items), emotional functioning (5 items), social functioning (5 items) and academic functioning (5 items). The parent questionnaire assesses parents' perceptions of their child's health-related quality of life.
Time frame: From the end of surgery up to 6 postoperative months
Started Feb 2025 (actual). Primary completion is estimated for Jul 2028, 41 months after the start.
Of 125 non-industry phase 2 interventional studies under Pain, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 60. This study's planned 41 months is above that.
Counting every sponsor, half of 187 studies reached it within 21 months; a quarter within 8 and three quarters within 40.
Primary completion moved once since we started tracking on Sep 25, 2026: Jul 2027 → Jul 2028, on Oct 13, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dexmedetomidine
University Hospital, Montpellier →